Therapeutic IgG-Like Bispecific Antibodies: Modular Versatility and Manufacturing Challenges

Since 1986, when the US Food and Drug Administration approved the first mouse monoclonal antibody (MAb) for clinical use, the global market for MAbs has expanded dramatically.

The success of this drug class has stimulated research into novel protein engineering methods, from which has come new bispecific antibodies (bsAbs), divided in IgG-like bsAbs and non–IgG-like bsAbs based on their structure.

Our experts conducted a deep evaluation of IgG-like bsAbs. The evaluation included general advantages and disadvantages compared with MAbs; described different formats and structural characteristics; and outlined how IgG-like bsAbs are applied in medical research as well as manufacturing considerations.

Access the article series “Therapeutic IgG-Like Bispecific Antibodies: Modular Versatility and Manufacturing Challenges” published by BioProcess International:

• “Therapeutic IgG-Like Bispecific Antibodies: Modular Versatility and Manufacturing Challenges” (part 1)
• Therapeutic IgG-Like Bispecific Antibodies: Modular Versatility and Manufacturing Challenges” (part 2)

Experts behind the articles:

• Jennifer Bratt
• Angela Linderholm
• Bryan Monroe
• Steven M. Chamow

Contact us to discover how our team’s comprehensive knowledge in biologics, MAbs, and bsAbs products can make a significant difference in your development journey.